Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Benzinga · 05/02 12:40
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.